Global Conjugate Vaccine Market Insights and Forecast to 2027

1 Study Coverage

• 1.1 Conjugate Vaccine Product Introduction
• 1.2 Market by Type
  • 1.2.1 Global Conjugate Vaccine Market Size Growth Rate by Type
  • 1.4.2 Hib Vaccine
  • 1.4.3 Meningococcal Vaccine
  • 1.2.4 Pneumococcal Vaccine
  • 1.2.5 Others
• 1.3 Market by End Users
  • 1.3.1 Global Conjugate Vaccine Market Size Growth Rate by End Users
  • 1.3.2 Children
  • 1.3.3 Adult
• 1.4 Study Objectives
• 1.5 Years Considered

2 Executive Summary

• 2.1 Global Conjugate Vaccine Sales Estimates and Forecasts 2016-2027
• 2.2 Global Conjugate Vaccine Revenue Estimates and Forecasts 2016-2027
• 2.3 Global Conjugate Vaccine Revenue by Region: 2016 VS 2021 VS 2027
• 2.4 Global Top Conjugate Vaccine Regions by Sales
  • 2.4.1 Global Top Conjugate Vaccine Regions by Sales (2016-2021)
  • 2.4.2 Global Top Conjugate Vaccine Regions by Sales (2022-2027)
• 2.5 Global Top Conjugate Vaccine Regions by Revenue
  • 2.5.1 Global Top Conjugate Vaccine Regions by Revenue (2016-2021)
  • 2.5.2 Global Top Conjugate Vaccine Regions by Revenue (2022-2027)
• 2.6 North America
• 2.7 Europe
• 2.8 Asia-Pacific
• 2.9 Latin America
• 2.10 Middle East & Africa

3 Competition by Manufacturers

• 3.1 Global Conjugate Vaccine Sales by Manufacturers
  • 3.1.1 Global Top Conjugate Vaccine Manufacturers by Sales (2016-2021)
  • 3.1.2 Global Top Conjugate Vaccine Manufacturers Market Share by Sales (2016-2021)
  • 3.1.3 Global Top 10 and Top 5 Companies by Conjugate Vaccine Sales in 2020
• 3.2 Global Conjugate Vaccine Revenue by Manufacturers
  • 3.2.1 Global Top Conjugate Vaccine Manufacturers by Revenue (2016-2021)
  • 3.2.2 Global Top Conjugate Vaccine Manufacturers Market Share by Revenue (2016-2021)
  • 3.2.3 Global Top 10 and Top 5 Companies by Conjugate Vaccine Revenue in 2020
• 3.3 Global Conjugate Vaccine Sales Price by Manufacturers
• 3.4 Analysis of Competitive Landscape
  • 3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Conjugate Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
  • 3.4.3 Global Conjugate Vaccine Manufacturers Geographical Distribution
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Global Conjugate Vaccine Sales by Type
  • 4.1.1 Global Conjugate Vaccine Historical Sales by Type (2016-2021)
  • 4.1.2 Global Conjugate Vaccine Forecasted Sales by Type (2022-2027)
  • 4.1.3 Global Conjugate Vaccine Sales Market Share by Type (2016-2027)
• 4.2 Global Conjugate Vaccine Revenue by Type
  • 4.2.1 Global Conjugate Vaccine Historical Revenue by Type (2016-2021)
  • 4.2.2 Global Conjugate Vaccine Forecasted Revenue by Type (2022-2027)
  • 4.2.3 Global Conjugate Vaccine Revenue Market Share by Type (2016-2027)
• 4.3 Global Conjugate Vaccine Price by Type
  • 4.3.1 Global Conjugate Vaccine Price by Type (2016-2021)
  • 4.3.2 Global Conjugate Vaccine Price Forecast by Type (2022-2027)

5 Market Size by Application

• 5.1 Global Conjugate Vaccine Sales by End Users
  • 5.1.1 Global Conjugate Vaccine Historical Sales by End Users (2016-2021)
  • 5.1.2 Global Conjugate Vaccine Forecasted Sales by End Users (2022-2027)
  • 5.1.3 Global Conjugate Vaccine Sales Market Share by End Users (2016-2027)
• 5.2 Global Conjugate Vaccine Revenue by End Users
  • 5.2.1 Global Conjugate Vaccine Historical Revenue by End Users (2016-2021)
  • 5.2.2 Global Conjugate Vaccine Forecasted Revenue by End Users (2022-2027)
  • 5.2.3 Global Conjugate Vaccine Revenue Market Share by End Users (2016-2027)
• 5.3 Global Conjugate Vaccine Price by End Users
  • 5.3.1 Global Conjugate Vaccine Price by End Users (2016-2021)
  • 5.3.2 Global Conjugate Vaccine Price Forecast by End Users (2022-2027)

6 North America

• 6.1 North America Conjugate Vaccine Market Size by Type
  • 6.1.1 North America Conjugate Vaccine Sales by Type (2016-2027)
  • 6.1.2 North America Conjugate Vaccine Revenue by Type (2016-2027)
• 6.2 North America Conjugate Vaccine Market Size by End Users
  • 6.2.1 North America Conjugate Vaccine Sales by End Users (2016-2027)
  • 6.2.2 North America Conjugate Vaccine Revenue by End Users (2016-2027)
• 6.3 North America Conjugate Vaccine Market Size by Country
  • 6.3.1 North America Conjugate Vaccine Sales by Country (2016-2027)
  • 6.3.2 North America Conjugate Vaccine Revenue by Country (2016-2027)
  • 6.3.3 U.S.
  • 6.3.4 Canada

7 Europe

• 7.1 Europe Conjugate Vaccine Market Size by Type
  • 7.1.1 Europe Conjugate Vaccine Sales by Type (2017-2027)
  • 7.1.2 Europe Conjugate Vaccine Revenue by Type (2017-2027)
• 7.2 Europe Conjugate Vaccine Market Size by End Users
  • 7.2.1 Europe Conjugate Vaccine Sales by End Users (2017-2027)
  • 7.2.2 Europe Conjugate Vaccine Revenue by End Users (2017-2027)
• 7.3 Europe Conjugate Vaccine Market Size by Country
  • 7.3.1 Europe Conjugate Vaccine Sales by Country (2017-2027)
  • 7.3.2 Europe Conjugate Vaccine Revenue by Country (2017-2027)
  • 7.3.3 Germany
  • 7.3.4 France
  • 7.3.5 U.K.
  • 7.3.6 Italy
  • 7.3.7 Russia

8 Asia Pacific

• 8.1 Asia Pacific Conjugate Vaccine Market Size by Type
  • 8.1.1 Asia Pacific Conjugate Vaccine Sales by Type (2018-2027)
  • 8.1.2 Asia Pacific Conjugate Vaccine Revenue by Type (2018-2027)
• 8.2 Asia Pacific Conjugate Vaccine Market Size by End Users
  • 8.2.1 Asia Pacific Conjugate Vaccine Sales by End Users (2018-2027)
  • 8.2.2 Asia Pacific Conjugate Vaccine Revenue by End Users (2018-2027)
• 8.3 Asia Pacific Conjugate Vaccine Market Size by Region
  • 8.3.1 Asia Pacific Conjugate Vaccine Sales by Region (2018-2027)
  • 8.3.2 Asia Pacific Conjugate Vaccine Revenue by Region (2018-2027)
  • 8.3.3 China
  • 8.3.4 Japan
  • 8.3.5 South Korea
  • 8.3.6 India
  • 8.3.7 Australia
  • 8.3.8 Taiwan
  • 8.3.9 Indonesia
  • 8.3.10 Thailand
  • 8.3.11 Malaysia
  • 8.3.12 Philippines

9 Latin America

• 9.1 Latin America Conjugate Vaccine Market Size by Type
  • 9.1.1 Latin America Conjugate Vaccine Sales by Type (2019-2027)
  • 9.1.2 Latin America Conjugate Vaccine Revenue by Type (2019-2027)
• 9.2 Latin America Conjugate Vaccine Market Size by End Users
  • 9.2.1 Latin America Conjugate Vaccine Sales by End Users (2019-2027)
  • 9.2.2 Latin America Conjugate Vaccine Revenue by End Users (2019-2027)
• 9.3 Latin America Conjugate Vaccine Market Size by Country
  • 9.3.1 Latin America Conjugate Vaccine Sales by Country (2019-2027)
  • 9.3.2 Latin America Conjugate Vaccine Revenue by Country (2019-2027)
  • 9.3.3 Mexico
  • 9.3.4 Brazil
  • 9.3.5 Argentina

6 Middle East and Africa

• 6.1 Middle East and Africa Conjugate Vaccine Market Size by Type
  • 6.1.1 Middle East and Africa Conjugate Vaccine Sales by Type (2016-2027)
  • 6.1.2 Middle East and Africa Conjugate Vaccine Revenue by Type (2016-2027)
• 6.2 Middle East and Africa Conjugate Vaccine Market Size by End Users
  • 6.2.1 Middle East and Africa Conjugate Vaccine Sales by End Users (2016-2027)
  • 6.2.2 Middle East and Africa Conjugate Vaccine Revenue by End Users (2016-2027)
• 6.3 Middle East and Africa Conjugate Vaccine Market Size by Country
  • 6.3.1 Middle East and Africa Conjugate Vaccine Sales by Country (2016-2027)
  • 6.3.2 Middle East and Africa Conjugate Vaccine Revenue by Country (2016-2027)
  • 6.3.3 Turkey
  • 6.3.4 Saudi Arabia
  • 6.3.5 U.A.E

11 Company Profiles

• 11.1 Pfizer
  • 11.1.1 Pfizer Corporation Information
  • 11.1.2 Pfizer Overview
  • 11.1.3 Pfizer Conjugate Vaccine Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.1.4 Pfizer Conjugate Vaccine Product Description
  • 11.1.5 Pfizer Related Developments
• 11.2 GSK
  • 11.2.1 GSK Corporation Information
  • 11.2.2 GSK Overview
  • 11.2.3 GSK Conjugate Vaccine Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.2.4 GSK Conjugate Vaccine Product Description
  • 11.2.5 GSK Related Developments
• 11.3 Sanofi
  • 11.3.1 Sanofi Corporation Information
  • 11.3.2 Sanofi Overview
  • 11.3.3 Sanofi Conjugate Vaccine Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.3.4 Sanofi Conjugate Vaccine Product Description
  • 11.3.5 Sanofi Related Developments
• 11.4 Merck
  • 11.4.1 Merck Corporation Information
  • 11.4.2 Merck Overview
  • 11.4.3 Merck Conjugate Vaccine Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.4.4 Merck Conjugate Vaccine Product Description
  • 11.4.5 Merck Related Developments
• 11.5 Walvax Biotechnology
  • 11.5.1 Walvax Biotechnology Corporation Information
  • 11.5.2 Walvax Biotechnology Overview
  • 11.5.3 Walvax Biotechnology Conjugate Vaccine Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.5.4 Walvax Biotechnology Conjugate Vaccine Product Description
  • 11.5.5 Walvax Biotechnology Related Developments
• 11.6 Royal (Wuxi) Bio-Pharmaceutical
  • 11.6.1 Royal (Wuxi) Bio-Pharmaceutical Corporation Information
  • 11.6.2 Royal (Wuxi) Bio-Pharmaceutical Overview
  • 11.6.3 Royal (Wuxi) Bio-Pharmaceutical Conjugate Vaccine Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.6.4 Royal (Wuxi) Bio-Pharmaceutical Conjugate Vaccine Product Description
  • 11.6.5 Royal (Wuxi) Bio-Pharmaceutical Related Developments
• 11.7 Bharat Biotech
  • 11.7.1 Bharat Biotech Corporation Information
  • 11.7.2 Bharat Biotech Overview
  • 11.7.3 Bharat Biotech Conjugate Vaccine Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.7.4 Bharat Biotech Conjugate Vaccine Product Description
  • 11.7.5 Bharat Biotech Related Developments
• 11.8 Zhifei Biologic
  • 11.8.1 Zhifei Biologic Corporation Information
  • 11.8.2 Zhifei Biologic Overview
  • 11.8.3 Zhifei Biologic Conjugate Vaccine Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.8.4 Zhifei Biologic Conjugate Vaccine Product Description
  • 11.8.5 Zhifei Biologic Related Developments
• 11.1 Pfizer
  • 11.1.1 Pfizer Corporation Information
  • 11.1.2 Pfizer Overview
  • 11.1.3 Pfizer Conjugate Vaccine Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.1.4 Pfizer Conjugate Vaccine Product Description
  • 11.1.5 Pfizer Related Developments

12 Value Chain and Sales Channels Analysis

• 12.1 Conjugate Vaccine Value Chain Analysis
• 12.2 Conjugate Vaccine Key Raw Materials
  • 12.2.1 Key Raw Materials
  • 12.2.2 Raw Materials Key Suppliers
• 12.3 Conjugate Vaccine Production Mode & Process
• 12.4 Conjugate Vaccine Sales and Marketing
  • 12.4.1 Conjugate Vaccine Sales Channels
  • 12.4.2 Conjugate Vaccine Distributors
• 12.5 Conjugate Vaccine Customers

13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis

• 13.1 Conjugate Vaccine Industry Trends
• 13.2 Conjugate Vaccine Market Drivers
• 13.3 Conjugate Vaccine Market Challenges
• 13.4 Conjugate Vaccine Market Restraints

14 Key Findings in The Global Conjugate Vaccine Study

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Author Details